Regencell Bioscience Holdings Limited
RGC
株式のランク
#3383
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
株価
$10.41
最終同期: 2026-10-20
時価総額
$5.16B
変化（1日）
3.56%
変化（1年）
-35.07%
国
HK
取引 Regencell Bioscience Holdings Limited (RGC)
カテゴリー
Healthcare
Regencell Bioscience Holdings Limited（RGC）のP/B比率
October 2026 時点のP/B比率 TTM: 300.54
Regencell Bioscience Holdings Limited の最新の財務報告および株価によると、現在のP/B比率（TTM）は 300.54 です。2024 年末時点でのP/B比率は 5.08 でした。
Regencell Bioscience Holdings Limited の P/B 比率の履歴（2019 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 300.54 | -82.66% |
| 2025 | 1.73K | 34,010.49% |
| 2024 | 5.08 | -79.61% |
| 2023 | 24.92 | -5.54% |
| 2022 | 26.38 | -179.45% |
| 2021 | -33.21 | -33.69% |
| 2020 | -50.08 | -30.65% |
| 2019 | -72.20 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -98.32% |
IN
|
